Reimbursement standards have been prepared for the use of combination therapy in biliary tract cancer in Korea. However, in consideration of health insurance finances, patients are required to the full cost of the high-priced immuno-oncology drugs.

The Health Insurance Review and Assessment Service recently added the combination of immuno-oncology Imfinzi (durvalumab) with gemcitabine and cisplatin to the biliary tract cancer reimbursement standards after an opinion survey on the amendment to the notification on medicines prescribed and administered to cancer patients.

This is the first time an immuno-oncology drug regimen has been added for biliary tract cancer. HIRA said that th